Lung Adenocarcinoma
Conditions
Brief summary
Brain metastasis of lung cancer is one of the most important metastasis pathways in patients with life-threatening diseases. This study explore the efficacy and safety of Tislelizumab combining with platinum-containing drug chemotherapy in the first-line treatment of Lung Adenocarcinoma With Asymptomatic Brain Metastatic. Meanwhile, Related biomarkers were explored to provide theoretical basis for efficacy evaluation and resistance mechanism.
Interventions
DRUGTislelizumab,Platinum
1. Induction therapy stage: Tislelizumab plus platinum-containing drug chemotherapy was administered every 3 weeks and was expected to complete 6 cycles of treatment. 2. Maintenance treatment phase: After completion of the induction therapy phase, patients whose antitumor response was confirmed as complete response, partial response, and disease stable according to RECIST v1.1 criteria were admitted to maintenance therapy .
Sponsors
Hebei Medical University Fourth Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with metastatic (stage IV) lung adenocarcinoma who have not been systematically treated and are histologically or cytologically confirmed as unable to undergo radical surgery or radiotherapy based on AJCC Stage VIII; 2. Patients with brain metastases confirmed by imaging; 3. Patients with asymptomatic BMS after initial diagnosis, local BMS surgery or radiotherapy; 4. ECOG PS: 0-1; 5. Measurable target lesions outside the skull (as per RECIST 1.1); 6. Life expectancy greater than 3 months;
Exclusion criteria
1. Patients had been treated with immune checkpoint inhibitors such as anti-PD-1, PD-L1, or CTLA-4 therapy; 2. The patient had received systemic chemotherapy as advanced treatment; 3. Patients with EGFR mutation or ALK gene translocation; 4. The patient had received approved systemic anticancer therapy or systemic immunomodulators (including but not limited to interferon, interleukin 2, and tumor necrosis factor) within 4 weeks prior to initial administration; 5. Clinically uncontrolled pleural fluid or ascites requiring puncture drainage within 2 weeks prior to initial administration;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1 years PFS | up to 1year | the time from the date of first dose of study treatment to the date of first documentation of disease progression using RECIST v1.1 or death, whichever occurs first |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The objective response rate (ORR) | Through study completion, an average of 12 months | Assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 |
Countries
China
Contacts
Primary ContactJian Shi, Dr.
Outcome results
None listed